Shots:
- The NMPA has accepted and granted priority review to NDA of Orpathys (savolitinib) + Tagrisso (osimertinib) for treating locally advanced or metastatic EGFR-mutated NSCLC with MET amplification in patients progressed on 1L EGFR inhibitor therapy. HUTCHMED will receive milestone from AstraZeneca
- Submission was based on P-III (SACHI) study assessing the safety & efficacy of Orpathys + Tagrisso vs Pt-based doublet-CT (pemetrexed plus cisplatin or carboplatin) in this population
Study achieved its 1EP of PFS in a planned interim analysis, as confirmed by the Independent Data - Monitoring Committee (IDMC). Enrollment is now complete, and results will be highlighted at future conferences
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED’s Orpathys and Tagrisso Combination Secures the NMPA’s Breakthrough Therapy Designation for Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
